Background: To determine the mechanisms associated with loss of androgen dependency
and disease progression in prostate cancer (PCa), we investigated the relationship between …

Background Prostate epithelial cells depend on androgens for survival and function. In
(early) prostate cancer (PCa) androgens also regulate tumor growth, which is exploited by …

The development of castration-resistant prostate cancer (CRPC) is associated with the
activation of intratumoral androgen biosynthesis and an increase in androgen receptor (AR) …

BACKGROUND The primary therapeutic target for non‐organ‐confined prostate cancer is
the androgen receptor (AR). Main strategies to ablate AR function are androgen depletion …

Androgens are key factors involved in the development and progression of prostate cancer
(PCa), and PCa growth can be suppressed by androgen deprivation therapy. In a …

Androgen deprivation therapy for advanced prostate cancer is often effective, but not
curative. Molecular pathways mediating the therapeutic response and those contributing to …

Prostate cancer is well known to be dependent on the androgen receptor (AR) for growth
and survival. Thus, AR is the main pharmacological target to treat this disease. However …

Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT)
is the mainstay of (metastatic) prostate cancer therapy. Ultimately, the AR pathway will be re …

Although androgen ablation therapy is the foundation of current prostate cancer treatment,
most patients ultimately develop castration-resistant disease. One proposed mechanism to …

Ionizing radiation (IR) is used frequently in the management of multiple tumor types,
including both organ-confined and locally advanced prostate cancer (PCa). Enhancing …